HealthQuill Clinical trials
AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to an antibody being tested for certain types of cancers and autoimmune conditions.
Drugs Health Pharma

AbbVie inks $2 billion deal with IGI, bags antibody to fight cancer 

HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.

Read More
The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults with early Alzheimer’s disease, including those with mild memory problems or mild dementia.
Drugs Health Pharma

FDA permits slow dosing of Eli Lilly’s Alzheimer’s drug Kisunla

HQ Team July 9, 2025: The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults.

Read More
KalVista Pharmaceuticals Inc.'s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks in the body, got approval from the US regulator. 
Drugs Health Pharma

KalVista’s oral pill for body swelling disorder gets US regulator’s nod 

HQ Team July 7, 2025: KalVista Pharmaceuticals Inc.’s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks.

Read More
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after it failed to meet its main efficacy goal.
Drugs Health Pharma

Organon halts endometriosis drug trial as it fails to meet efficacy goal

HQ Team July 2, 2025: Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after.

Read More
A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making it difficult to use the results in practice, according to researchers from the University of Copenhagen and the University of São Paulo.
Drugs Health Research

Researchers find serious flaws in clinical trials with adult ADHD patients

HQ Team July 2, 2025: A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making.

Read More
Amgen Inc.’s drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer compared to chemotherapy alone, according to a company statement.
Drugs Health Pharma

Amgen’s trial drug for gastric cancer patients helps them live longer

HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More